Daewoong Pharmaceutical's botulinum toxin is expanding its influence in the global toxin market by launching in the Oceania continent, following its presence in North America, South America, Europe, and Asia. Daewoong Pharmaceutical announced on August 19 that it has officially launched its botulinum toxin product in Australia through its global botulinum toxin partner, Evolus. The product will be marketed under the name 'NUCEIVA®' in Australia.
Daewoong's independently developed botulinum toxin product successfully entered the U.S. market in 2019 after receiving FDA approval.
With its high purity and quality, it has now entered five continents: North America, South America, Europe, Asia, and Oceania. In January of last year, Daewoong and Evolus obtained approval for NUCEIVA 100 units from the Australian Therapeutic Goods Administration (TGA). Evolus set up a booth and held a symposium launch event attended by over 200 participants at the 'Aesthetics 2024' held in Sydney, Australia, from August 1 to 4, where they first introduced NUCEIVA to local medical professionals.
Evolus plans to rapidly increase brand awareness through local education and seminars. Dr. Steven Liew, a plastic surgeon in Australia, stated, "There is a growing interest in aesthetics, such as non-surgical procedures, among the younger generation in Australia.
NUCEIVA will offer new options in the beauty field to Australian healthcare providers, helping to achieve optimal results tailored to patient prefere.